Birzeit Pharmaceutical

What Birzeit Pharmaceutical does

Birzeit Pharmaceutical is a publicly traded Palestinian manufacturer of generic medicines and pharmaceuticals, headquartered in Ramallah. Founded in 1937, the company is one of the longest-operating pharmaceutical manufacturers in the Palestinian market, currently employing between 251 and 500 people. Birzeit Pharmaceutical is listed on the Palestine Exchange (PEX) under the ticker symbol BPC, making it a publicly traded for-profit entity in the regional pharmaceutical sector.

The company operates as a generic pharmaceutical manufacturer, producing medicines likely intended for the Palestinian healthcare market and potentially surrounding regional markets. Its business model is rooted in the production and distribution of generic drug formulations, a segment that typically targets price-sensitive healthcare systems and consumers. However, the available source data is severely limited — the company's primary website (bpc.ps) was inaccessible (returning only a verification/loading page), and no detailed product portfolio, technology stack, distribution channels, pricing models, or financial metrics are present in the available data.

The absence of detailed disclosures on products, partnerships, certifications, management team, subsidiaries, and operational geography reflects a significant transparency gap for a publicly traded entity. This data gap limits rigorous analysis of competitive positioning, revenue mechanics, customer base, and growth trajectory. The firm's 87-year operating history and public listing status suggest a durable, established business, but the lack of substantive financial and operational data prevents deeper strategic assessment.

Name

Birzeit Pharmaceutical

Website

https://bpc.ps

Company type

Private

Founded year

1937

Headcount range

251–500 employees

Short description

Birzeit Pharmaceutical is a publicly traded Palestinian manufacturer of generic medicines and pharmaceuticals, founded in 1937 and headquartered in Ramallah. It serves the Palestinian healthcare market and is listed on the Palestine Exchange (PEX:BPC) with 251-500 employees.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Generic medicines
• Pharmaceutical manufacturing
• Drug manufacturing
• Human medicines

Headquarters

HQ city

Ramallah

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Infrastructure, Technology or R&D

Core offering

Birzeit Pharmaceutical is a manufacturer of generic medicines and pharmaceutical products. The company produces finished generic drug formulations for the Palestinian and regional healthcare market, operating as a physical-goods manufacturer rather than a software, platform, or pure-service provider. Founded in 1937 and headquartered in Ramallah, it is publicly listed on the Palestine Exchange (pex:BPC).

Product overview

No product or service information available. The source displays a loading/verification page with no accessible content.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic pharmaceutical products Generic medicines and pharmaceutical products manufactured by Birzeit Pharmaceutical for the healthcare market. Sold to pharmaceutical distributors, pharmacy chains, hospitals, clinics, and public-sector health buyers.

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights1 record

Direct peers

• Jazeera Pharmaceutical Industries (JPI): JPI is a Saudi Arabian generic pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables for local and regional markets. Its focus on affordable generics for the MENA region mirrors Birzeit's positioning.
• Tabuk Pharmaceuticals: Tabuk is a Saudi pharmaceutical company manufacturing generics, branded generics, and biosimilars primarily for MENA markets. Overlaps with Birzeit in generic small-molecule manufacturing and regional customer base.
• Gulf Pharmaceutical Industries (Julphar): Julphar is a UAE-based generic pharmaceutical manufacturer with a large MENA and emerging-markets footprint. It competes with Birzeit for regional generic tenders and offers a comparable product mix of small-molecule generics.
• Pharco Pharmaceuticals: Pharco is a leading Egyptian generic pharmaceutical manufacturer with significant MENA and African market presence. Overlaps with Birzeit as a regional generic manufacturer focused on affordable essential medicines.
• SPIMACO Addwaeih: SPIMACO is one of the largest Saudi generic pharmaceutical manufacturers, producing a wide range of dosage forms for regional and export markets. Comparable to Birzeit as a regional generic manufacturer competing for similar public-sector tenders.
• EIPICO (Egyptian International Pharmaceutical Industries): EIPICO is one of the largest Egyptian generic pharmaceutical manufacturers, producing a broad range of dosage forms for domestic and export markets across the Arab world. Comparable business model and regional target markets to Birzeit.
• Hikma Pharmaceuticals: Hikma is a Jordan-headquartered generic and specialty pharmaceutical manufacturer with a broad MENA and US footprint. It is the closest regional peer to Birzeit in terms of business model (generic small molecules) and target markets (Arab-world public and private healthcare procurement).

Broad incumbents

• Cipla: Cipla is a major Indian-headquartered generic pharmaceutical manufacturer with a strong presence across Africa, the Middle East, and other emerging markets. Comparable as a globally scaled supplier of affordable generics to developing-market healthcare systems.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer and is regionally relevant as an Israeli-headquartered incumbent with deep ties to the local pharmaceutical market. It represents the dominant incumbent competitive threat in the same geographic area as Birzeit.
• Aspen Pharmacare: Aspen is a large South African-headquartered generic and specialty pharmaceutical manufacturer with global emerging-markets reach. Comparable as a scaled generic manufacturer competing in similar price-sensitive public-procurement markets.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights4 records

Customer concentration

• Facebookfacebook.com/bpcpharm
• LinkedInlinkedin.com/company/birzeit-pharmaceutical

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Birzeit Pharmaceutical